Company / Current Liabilities
ADMA Biologics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$69.5M
FY2025
5-year range
$30.4M / $69.5M
FY2021-FY2025
Trend
+25.2%
vs FY2024
Sector context
#121 of 213
Health Care
What the data says
At $70M, ADMA Biologics, Inc.'s current liabilities ranks #93 of 213 in the Health Care sector. Current Liabilities has increased for 8 consecutive years, from $9M in FY2017 to $70M in FY2025.
Based on SEC 10-K filings.
$70M in FY2025 with a 5-year CAGR of +28.4%.
Increased from $50M to $70M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +21.0%
- 5-Year CAGR
- +28.4%
- 10-Year CAGR
- -
Sector benchmark
#93 of 213 in Health CareTop 43% of 213This company $69.5M Sector average $1.6B
▼
-95.6% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s current liabilities has grown for 8 consecutive years.
- 5-year CAGR of +28.4%, indicating consistent growth.
- In FY2025, current liabilities increased 25.2% year-over-year.
- Ranks #121 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $69.5M | +25.2% |
| FY2024 | $55.5M | +11.5% |
| FY2023 | $49.8M | +26.8% |
| FY2022 | $39.3M | +29.3% |
| FY2021 | $30.4M | +52.3% |
| FY2020 | $19.9M | +42.2% |
| FY2019 | $14.0M | +45.7% |
| FY2018 | $9.6M | +2.0% |
| FY2017 | $9.4M | -15.9% |
| FY2016 | $11.2M | +166.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026